IN8Bio Presented Results From The Fully Enrolled Phase 1 Trial Of INB-200 At The Annual Meeting Society For Neuro-oncology

in8bio在神经肿瘤学会年会上报告了INb-200完全招满的一期试验结果。

Benzinga · 2024/11/25 20:08

50% of patients who received repeated doses (n=10) remained alive and in remission beyond the expected median overall survival (OS) from standard-of-care Stupp regimen while none of the patients who received a single dose (n=3) achieved this outcome.
Biopsy results confirmed the presence and persistence of gamma-delta T cells along with CD3+ and CD8+ T cells within the brain tumor microenvironment in two patients following treatment with INB-200.
Patients in the multi-dose cohorts demonstrated a trend toward improved peripheral T cell recovery, suggesting potential immune system benefits.
The majority of patients exceeded their expected progression free survival (PFS) based on age and tumor status; five patients remain alive and three patients have returned to their occupations, with one patient remaining progression free at 40.5 months post treatment.

接受重复剂量（n=10）的患者中有50%在预期标准护理Stupp方案的中位总生存期（OS）之后仍然存活并处于缓解状态，而接受单剂量（n=3）的患者中没有人实现这一结果。
活检结果确认在接受INb-200治疗后，两名患者的脑肿瘤微环境中存在和持续 gamma-delta T 细胞以及 CD3+ 和 CD8+ T 细胞。
多剂量队列中的患者表现出周围 T 细胞恢复改善的趋势，暗示潜在的免疫系统益处。
大多数患者的预期无进展生存期（PFS）超过其年龄和肿瘤状态；五名患者仍然存活，三名患者已恢复工作，其中一名患者在治疗后40.5个月仍然无进展。

声明：本内容仅用作提供资讯及教育之目的，不构成对任何特定投资或投资策略的推荐或认可。更多信息

风险及免责提示